UAE Nutritional Supplements Market Analysis Sample Report

UAE Nutritional
Supplements Market
Analysis
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of the UAE Nutritional
Supplements Market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, types of clinical diagnostics, point-of-care testing,
main players, growth and demand drivers, challenges & future outlook, etc.
This is one of the most comprehensive reports about the UAE Nutritional
Supplements Market, and offers unmatched value, accuracy, and expert
insights

3
A Sample Report on UAE Nutritional Supplements Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Nutritional Supplements Overview 12-25
1.1. Overview
1.2. UAE Overview
1.3. Economic Overview: UAE
1.4. Nutritional Supplements Market in UAE
1.5. OTC & Nutraceuticals Market in UAE
1.6. Healthcare Scenario in UAE
1.7. Health Insurance Coverage: UAE
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 26-32
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. Technology Outlook
2.2.2. By Consumer Group
2.2.3. ByFormulations
2.2.4. By Delivery Channel
3. Market Dynamics 33-37
3.1. Market Growth Drivers
3.1.1. Increasing Health Consciousness
3.1.2. Rising Prevalence of Lifestyle Diseases
3.1.3. Medical Recommendations and Prescription
3.2. Market Restraints
3.2.1. Strict Regulations

6
Table of Content
CONTENT PG. NO.
3.2.2. Lack of Awareness
3.2.3 Price Sensitivity
4. Competitive Landscape 38-48
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Amway
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. Herbalife

7
Table of Content
CONTENT PG. NO.
4.2.2.1. Overview
4.2.3. Forever Living
4.2.3.1. Overview
4.2.4. Nature's Bounty

8
Table of Content
CONTENT PG. NO.
4.2.4.1. Overview
4.2.5. GNC
4.2.5.1. Overview
4.2.6. Optimum Nutrition

9
Table of Content
CONTENT PG. NO.
4.2.6.1. Overview
4.2.7. Nutrilite
4.2.7.1. Overview
4.2.8. Muscletech

10
Table of Content
CONTENT PG. NO.
4.2.8.1. Overview
4.2.9. Life Extension
4.2.9.1. Overview
4.2.10. Swisse

11
Table of Content
CONTENT PG. NO.
4.2.10.1. Overview
5. Reimbursement Scenario 49-56
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
5.4 Reimbursement Process – Medicare
5.5 Reimbursement Process - Medicaid
6. Methodology & Scope 57-62

UAE Nutritional Supplements Market Analysis
1. Nutritional Supplements Overview

13
1.1 Statistics at a Glance: The Burden of Nutritional deficiencies in the World
Prevalence of Nutritional Deficiencies ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
25%
of people affected iron
deficiency worldwide
3rd
of the world’s population
affected by Iodine
deficiency
44–50%
of preschool-aged
children in certain
regions have vitamin A
deficiency in developing
countries
15% and 10%of
teenage girls and over
50 aged women
recommended calcium
intake respectively in the
US
80–90%
of vegetarians and
vegans may be
deficient in vitamin
B12
42%
of people deficient of
vitamin D in the US

14
1.1 Overview of Nutritional Supplements Market in the World (continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of $xx
Bn
Middle East
~$xx Bn Market

15
1.2 UAE Overview
9.37 Mn
Is the population of
UAE, in 2021
28.2
is the median age
in UAE, in 2022
$47,792
GDP per Capita in
2022
$498.98 Bn
GDP in 2022
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
Illustrative

16
1.3 Economic Overview: UAE
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of UAE, (2020-2030)
XX
XX
2020 2021 2022 2023F2024F2025F2026F2027F2028F2029F2023F
GDP of UAE, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Statistics at a Glance: The Burden of Nutritional deficiencies in UAE
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in UAE
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
24.3%
of women aged 15 to 49
years affected by anemia
due to iron deficiency
90%
of UAE population Vitamin D
deficient
22%
of the infants were anemic
35.6%
aged 18 to 24 years are
using dietry supplements in
UAE
6%
Infants were wasted
29.4%
males preferred protein
supplements
29.4%
males preferred protein
supplements
68.3%
Dietary supplements users agreed
its essential
Prevalence of Nutritional Deficiencies and Dietary
Supplements Use in UAE

18
1.5 OTC & Nutraceuticals in UAE
XX XX XX XX XX XX XX XX XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
UAE OTC & Nutraceuticals Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall OTC & Nutraceuticals market in UAE, which includes the market size, current
trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

19
1.6 Healthcare Scenario in UAE
▪ UAE has state-of-the-art healthcare infrastructure, including modern hospitals, clinics, and specialized medical centers. The country has
established free zones such as Dubai Healthcare City and Abu Dhabi Health Services Company (SEHA) to attract international
healthcare providers and promote medical tourism
▪ UAE has a dual healthcare system consisting of public and private sectors. The Ministry of Health and Prevention (MOHAP) oversees
public healthcare facilities, which provide subsidized or free services to Emirati citizens
▪ AE places a strong emphasis on healthcare quality and accreditation. The Dubai Health Authority (DHA) and the Health Authority Abu
Dhabi (HAAD) regulate healthcare providers and ensure adherence to international standards
▪ Health insurance is mandatory for residents in the UAE. Employers are generally responsible for providing health insurance coverage to their
employees
Evaluation and
Assessment
▪ The MOHAP evaluates the submitted data, including preclinical and clinical trial results, to assess the drug's safety,
efficacy, and quality.
Expert Committee
Review
▪ The MOHAP may convene an expert committee or advisory board comprising healthcare professionals, scientists,
and regulatory experts to provide their opinions and recommendations on the drug's approval
Approval Decision
▪ Based on the evaluation and expert committee recommendations, the MOHAP makes a decision regarding the
drug's approval
Post-Marketing
Surveillance
▪ Once a drug is approved and available in the market, the MOHAP continues to monitor its safety and effectiveness
through post-marketing surveillance
In the United Arab Emirates (UAE), the drug approval process is overseen by the Ministry of Health and Prevention (MOHAP)

20
1.6 Healthcare Scenario: Nutritional Deficeiency Patient Journey
• Patient experiences symptoms that
may indicate a nutritional deficiency,
such as fatigue, weakness, hair loss, or
specific signs related to a particular
deficiency
• Patient schedules an appointment
with a primary care physician or
general practitioner
• During the consultation, the patient
describes their symptoms, medical
history, and any relevant dietary or
lifestyle factors
• The doctor listens to the patient's
concerns and conducts a physical
examination
Symptom Recognition & Concern Primary Care Consultation Assessment & Initial Tests:
Treatment Plan Development Referral to a Specialist
▪ In some cases, the primary care
physician may refer the patient to a
specialist, such as a dietitian or
nutritionist, to provide more
specialized care and expertise
▪ The specialist can further evaluate the
patient's nutritional needs, develop a
personalized meal plan, and offer
ongoing support and monitoring
• Patient recognize these symptoms and
become concerned about their health
• Based on the patient's symptoms
and medical history, the doctor
assesses the likelihood of a
nutritional deficiency
• Doctor recommends initial blood
tests or other diagnostic
investigations to evaluate the
patient's nutrient levels or screen for
potential deficiencies.
• This may include tests for iron,
vitamin D, vitamin B12, folate, or
other relevant markers
Test Results & Diagnosis
• Once the test results are available, the
doctor reviews them and makes a
diagnosis regarding the presence and
severity of the nutritional deficiency
• They explain the implications of the
deficiency to the patient and discuss
potential causes
• The patient is informed about the
importance of proper nutrition and the role
it plays in overall health.
▪ Doctor develops a treatment plan tailored to the patient's
specific nutritional deficiency. This plan may involve dietary
modifications, lifestyle changes, and/or nutritional
supplements
▪ Doctor provides detailed instructions on dietary
recommendations, including specific foods to include or
avoid to address the deficiency
▪ They may also refer the patient to a dietitian or nutritionist
for further guidance
Follow-Up and Monitoring
▪ Patient is scheduled for follow-up
visits to monitor their progress and
evaluate the response to treatment.
▪ During these visits, the doctor or
specialist assesses the patient's
nutrient levels through repeated
blood tests, discusses any challenges
or concerns, and makes adjustments
to the treatment plan as necessary

21
1.7 Health Insurance Coverage: UAE
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar
year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by
Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
This is the US Health Insurance coverage, you will get UAE Health Insurance coverage in Final Report
Illustrative

22
1.8 Budget of UAE Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
This is the budget of the US govt. for public insurance, you will get UAE govt. for public insurance in Final Report

23
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

24
1.9 Mergers and Acquisitions (continued)
Latest Deals In UAE
Company Name Year Key Pointers
Abbott
September 2022
▪ Abbott launched a brand-new Ensure formulation with HMB. As a science-
based nutritional supplement, the new Ensure contains 32 essential nutrients
such as protein, calcium, and vitamin D to help improve muscle and bone
strength. It contains HMB or hydroxy-methyl butyrate, a new ingredient that
helps counteract muscle loss and increases the strength and power of the
body
Optimum Nutrition
August 2022:
▪ Optimum Nutrition, a Glanbia Performance Nutrition brand, launched its brand-
new Gold Standard Protein Shake. The new drink has two flavors: chocolate
and vanilla. Each serving contains 24 grams of protein.
PharmaNutrics
March 2022:
▪ PharmaNutrics launched five different dietary supplements in the United
States. SerotomixPlus, GlucanPlus, Gaba 600, EnergixPlux, and
CurcumixPlux serve different purposes for fatigue, stress, musculoskeleton,
and anti-inflammatory support.

25
1.9 Mergers and Acquisitions (continued)
Latest Deals In UAE
Company Name Year Key Pointers
2023
2023
2023
Illustrative

2. Market Size and Forecasting

27
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
UAE Nutritional Supplements Market Forecast, 2022-2030 (in $Bn)
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
UAE Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
UAE Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

28
2.2 Snapshot of Nutritional Supplements Market Segmentation
By Consumer Group By Formulations By Delivery Channel
Sports Nutrition
Fat Burners
Dietary Supplements
Functional Foods
Infant
▪ In this section you will get an understanding of the segmentations which will cover the UAE Nutritional Supplements Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Product
Children
Adults
Chemists/
Pharmacists
Direct-to-Consumer
Sales Payers
E-commerce
Pregnant
Geriatric
Tablets
Capsules
Powder
Softgels
Liquid

29
UAE Nutritional Supplements Market Share, By Product Type (2022)
Dietary
Supplements
Sports Nutrition
Fat Burners
Functional Foods
▪ Dietary supplements market in UAE is
a significant component of the overall
cancer treatment market
final report
2.2.1 Market Segmentation: By Product Type
Illustrative

30
UAE Nutritional Supplements Market Share, By Consumer Group (2022)
Infants
Children
Adults
Pregnant
Geriatric
2.2.2 Market Segmentation: By Consumer Group
▪ Infants dietary supplements market in
UAE is a significant component of the
overall cancer market
▪ It has the maximum market share in
UAE nutritional supplements market
with approximately xx%
final report
Illustrative

31
UAE Nutritional Supplements Market Share, By Formulations (2022)
Tablets
Capsules
Powder
Softgels
Liquid
2.2.3 Market Segmentation: By Formulations
▪ Tablets have the maximum market
share in UAE cancer market with
approximately xx%
final report
Illustrative

32
UAE Nutritional Supplements Market Share, By Delivery Channel (2022)
Chemists/
Pharmacists
Direct-to-
Consumer Sales
Payers
E-commerce
2.2.4 Market Segmentation: By Delivery Channel
▪ E-Commerce have the maximum
market share in UAE cancer market
with approximately xx%
final report
Illustrative

3. Market Dynamics

34
3.1 Market growth drivers
▪ There has been a growing awareness of the importance of nutrition and
maintaining a healthy lifestyle among the population in the UAE
▪ Individuals are becoming more health-conscious and proactive in seeking
ways to improve their overall well-being
▪ This increased focus on personal health and wellness has led to a
greater demand for nutritional supplements as a means to support their
dietary needs.
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest 2010 2022 2030
3.1.1 70% feel more in control of their health and 95% show proactiveness in protecting their health, the research
notes
Health Awareness Growth Rate

35
3.1 Market growth drivers (continued)
3.1.2 Noncommunicable diseases account for 76% of deaths in the UAE, and in recent years the country has seen a
rapid increase in diseases such as diabetes and obesity.
▪ UAE has witnessed an increase in the prevalence of lifestyle
diseases such as obesity, diabetes, and cardiovascular
disorders
▪ These health concerns have prompted individuals to adopt
healthier lifestyles and seek ways to prevent and manage
these conditions
▪ Nutritional supplements, including vitamins, minerals, and
herbal extracts, are seen as a convenient and accessible
option to complement a healthy diet and support overall
health.
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
2010 2022 2030
Prevalence of Non-Communicable
Diseases in UAE

36
3.1 Market growth drivers (continued)
Healthcare professionals recommend
nutritional supplements in UAE
3.1.3 Pharmacies across the UAE have been witnessing a marked increase sometimes as much as 100% in the
annual demand for multivitamins and supplements that claim to boost immunity amid the global pandemic
▪ Healthcare professionals, including doctors, dietitians, and
nutritionists, often recommend nutritional supplements to
individuals with specific nutrient deficiencies, chronic
diseases, or during pregnancy and lactation
▪ These recommendations and prescriptions have played a
role in driving the demand for nutritional supplements in the
UAE.
2010 2022 2030

37
3.2 Market restraints
3.2.1 UAE has strict
regulations governing
the sale, importation,
and marketing of
nutritional supplements
▪ Stringent regulatory framework
requires compliance with specific
labeling requirements, ingredient
standards, and product
registrations
▪ Obtaining necessary approvals
and complying with regulatory
requirements can be time-
consuming and costly for
manufacturers and distributors
▪ Stringent regulations act as a
barrier to entry for some
companies and may limit the
variety of products available in
the market
3.2.2 Despite increasing health
consciousness, there is still a
lack of widespread consumer
awareness of benefits of
nutritional supplements
▪ Many individuals may not be
aware of the specific nutritional
deficiencies they may have or
the potential benefits of
supplementing their diet with
appropriate products
▪ Insufficient education and
information about the importance
of proper nutrition and the
correct usage of supplements
can hinder market growth and
consumer adoption
3.2.3 Price sensitivity is a
significant constraint in the UAE
nutritional supplements market.
▪ Some consumers may perceive
nutritional supplements as
expensive, particularly high-
quality and branded products
▪ Affordability can be a challenge
for individuals with limited
disposable income or those who
consider nutritional supplements
as discretionary spending
▪ Price-conscious consumer
mindset may lead to hesitation or
limited purchasing power,
impacting market growth.
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.

4. Competitive Landscape

39
4.1 Major Market Share
▪ UAE cancer market is a highly competitive
space, with many companies developing
and marketing cancer treatments
▪ Some of the top companies in UAE cancer
market based on revenue and market
share include
interest
Revenue of Major players in UAE Nutritional Supplements Market ($ Mn)
XX
Company10
Company 1
Company 2
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Illustrative

40
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Amway
3 Forever Living
5 GNC
7 Nutrilite
9 Life Extension
2 Herbalife
4 Nature's Bounty
6 Optimum Nutrition
8 Muscletech
Swisse
10
Key Note:

41
4.2.1 Amway
Founded in: 1959
HQ: Ada, Michigan, US
Type: Privately-held
Revenue: $8.4 Bn
Website: www.amway.com
▪ Amway is a well-known global company that offers a range of
nutritional products under its Nutrilite brand.
▪ Amway's Nutrilite products are formulated based on scientific
research and manufactured using high-quality ingredients
▪ Company emphasizes the use of plant-based ingredients and
sustainable farming practices in the production of its supplements
▪ Nutrilite products undergo rigorous quality control processes to
ensure safety, purity, and potency
Key Executives
➢ Milind Pant - CEO
➢ Doug DeVos - Co-Chairman of
the Board
➢ Steve Van Andel - Co-Chairman
of the Board
➢ Samir Behl - Chief Financial
Officer (CFO)
Drugs for Cancer Recent Activity / Press Coverage
April 19, 2023: Amway has been named the No. 1 direct selling
company in the world, according to the 2023 Direct Selling News
Global 100 list based on 2022 revenue
December 12, 2022: Amway launches Singapore Business
Innovation Hub to accelerate health and wellness innovation
Feb. 27, 2023: Amway, an entrepreneur-led health and wellness
company, today reported sales of $8.1 billion USD for the year
ending December 31, 2022
Nutritional Supplements
Nutritional Education and
Resources
Weight Management Nutritional Analysis Tools
Sports Nutrition Weight Management Programs
Personalized Nutrition
Consultations
Community Support and
Networking

42
4.2.1 Amway (continued)

43
Company Name Type
Amount /
Duration
Year Key Pointers
Amway and HEM
Partnership -
August 15,
2022
▪ Amway has committed to a second-round investment with
Holzapfel Effective Microbes (HEM), a company that supports
people with incurable diseases related to microbiome disfunction
▪ HEM uses Personalized Pharmaceutical Meta-Analytical
Screening (PMAS) to determine how gut microbiota can be
leveraged to impact human health and wellness
Amway and ITC
Collabration - May 29, 2020
▪ TC’s B Natural and Amway India collaborate to launch immunity
offering in fruit beverages
▪ In a unique partnership, ITC’s B Natural and Amway India have
collaborated to launch the first of its kind B Natural+ range for the
Indian consumer
▪ B Natural Juices & beverages, which believes in providing fruit
nourishment to its consumers, intends to provide the dual benefit
of Immunity + Fruit & Fiber to them with the launch of the B
Natural + range
Latest Deals - Mergers and Acquisitions

44
XX
XX 8.9 Bn
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Amway annual revenue for 2022 was
$8.9.Bn , a XX% increase from 2021.
TELUS annual revenue for 2021 was $XX
BN, a XX% increase from 2020.
▪ Revenue generated by Telus Health in
2022 reflects the company's continued
growth and success in the healthcare
industry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

45
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

46
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

47
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

48
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

50
5.1 Reimbursement Regulation
The reimbursement scenario in the US cancer market is complex and can vary
depending on the specific treatment, setting of care, and insurance coverage.
Here are some key points to consider:
▪ Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many cancer treatments, including chemotherapy,
radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for cancer treatments can vary by state, and may be
subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Americans
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
This is the reimbursement regulation of of the US govt. for public insurance, you will get UAE reimbursement regulations in Final Report
Illustrative

51
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
This is the reimbursement regulation of of the US govt. for public insurance, you will get UAE reimbursement regulations in Final Report
Illustrative

52
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

53
5.2 Reimbursement Process for Diagnosis of Cancer
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
This is the reimbursement regulation of of the US govt. for public insurance, you will get reimbursement process in Final Report
Illustrative

54
5.3 Reimbursement Process for Treatment of Cancer
The reimbursement process in the US healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
This is the reimbursement regulation of of the US govt. for public insurance, you will get UAE reimbursement process in Final Report
Illustrative

55
5.4 Reimbursement Process - Medicare
Medicare
Population Covered
▪ 100% population is covered under this scheme
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
This is the reimbursement process of of the US govt. for public insurance, you will get Canada reimbursement process in Final Report
Illustrative

56
5.5 Reimbursement Process - Medicaid
Medicaid
Population Covered
▪ 38% population is covered under this scheme
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
This is the reimbursement process of of the US govt. for public insurance, you will get Canada reimbursement process in Final Report
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in OTC & Nutraceuticals
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
OTC & Nutraceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

UAE Nutritional Supplements Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to UAE Nutritional Supplements Market Analysis Sample Report

Similar to UAE Nutritional Supplements Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

UAE Nutritional Supplements Market Analysis Sample Report